Investor's Business Daily on MSN12m
Novo Nordisk Jumps After Ozempic Decidedly Beats. But 'Periodic Supply Constraints' Expected.
Novo Nordisk stock jumped early Wednesday after the weight-loss drugs leader reported adjusted earnings of 88 cents per share ...
Novo Nordisk CEO Lars Fruergaard Jørgensen on Q4 results, Wegovy demand and drug pipeline outlook
CNBC’s Angelica Peebles and Novo Nordisk CEO Lars Fruergaard Jørgensen join 'Squawk Box' to discuss the company's quarterly ...
Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...